Literature DB >> 24119423

Male hypogonadism.

Shehzad Basaria1.   

Abstract

Male hypogonadism is a clinical syndrome that results from failure to produce physiological concentrations of testosterone, normal amounts of sperm, or both. Hypogonadism may arise from testicular disease (primary hypogonadism) or dysfunction of the hypothalamic-pituitary unit (secondary hypogonadism). Clinical presentations vary dependent on the time of onset of androgen deficiency, whether the defect is in testosterone production or spermatogenesis, associated genetic factors, or history of androgen therapy. The clinical diagnosis of hypogonadism is made on the basis of signs and symptoms consistent with androgen deficiency and low morning testosterone concentrations in serum on multiple occasions. Several testosterone-replacement therapies are approved for treatment and should be selected according to the patient's preference, cost, availability, and formulation-specific properties. Contraindications to testosterone-replacement therapy include prostate and breast cancers, uncontrolled congestive heart failure, severe lower-urinary-tract symptoms, and erythrocytosis. Treatment should be monitored for benefits and adverse effects.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24119423     DOI: 10.1016/S0140-6736(13)61126-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  68 in total

1.  Is semen analysis necessary prior to the commencement of testosterone supplementation therapy in men of reproductive age?

Authors:  Michael Pan; Ranjith Ramasamy; Jason R Kovac
Journal:  Can Urol Assoc J       Date:  2014-11       Impact factor: 1.862

Review 2.  Testosterone therapy and prostate cancer--safety concerns are well founded.

Authors:  Laurence Klotz
Journal:  Nat Rev Urol       Date:  2015-01       Impact factor: 14.432

3.  A cross-sectional cadaveric study of the correlation between genital organ measurements, serum testosterone, and serum prostate-specific antigen levels in Japanese male subjects.

Authors:  Yuta Takeshima; Motofumi Suzuki; Hiroshi Ikegaya; Nozomi Idota; Taketo Kawai; Yusuke Sato; Haruki Kume
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2021-04-15

4.  Testosterone vs. aromatase inhibitor in older men with low testosterone: effects on cardiometabolic parameters.

Authors:  J P Dias; M D Shardell; O D Carlson; D Melvin; G Caturegli; L Ferrucci; C W Chia; J M Egan; S Basaria
Journal:  Andrology       Date:  2016-10-28       Impact factor: 3.842

5.  Glomerular hyperfiltration in hypogonadotropic hypogonadic patients: Overlooking a cache?

Authors:  Kerem Han Gözükara; Abdulmuttalip Arslan; Sadık Görür; Mehmet Murat Rifaioğlu; Ayşe Çarlıoğlu
Journal:  Int Urol Nephrol       Date:  2015-05-07       Impact factor: 2.370

Review 6.  Testosterone and prostate cancer: an evidence-based review of pathogenesis and oncologic risk.

Authors:  Jason E Michaud; Kevin L Billups; Alan W Partin
Journal:  Ther Adv Urol       Date:  2015-12

Review 7.  The role of nuclear hormone receptors in cutaneous wound repair.

Authors:  Sandra Rieger; Hengguang Zhao; Paige Martin; Koichiro Abe; Thomas S Lisse
Journal:  Cell Biochem Funct       Date:  2014-12-22       Impact factor: 3.685

Review 8.  Hormonal correlations of premature ejaculation.

Authors:  Andrea Sansone; Francesco Romanelli; Emmanuele A Jannini; Andrea Lenzi
Journal:  Endocrine       Date:  2015-01-01       Impact factor: 3.633

9.  Effects of Transdermal Testosterone Gel or an Aromatase Inhibitor on Prostate Volume in Older Men.

Authors:  Jenny Pena Dias; Denise Melvin; Michelle Shardell; Luigi Ferrucci; Chee W Chia; Mohsen Gharib; Josephine M Egan; Shehzad Basaria
Journal:  J Clin Endocrinol Metab       Date:  2016-03-07       Impact factor: 5.958

Review 10.  [The "obese" and "old" male patient in dermatological practice. When should hypogonadism be considered?].

Authors:  D Varwig-Janßen; F Ochsendorf
Journal:  Hautarzt       Date:  2015-12       Impact factor: 0.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.